Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Fiche publication
Date publication
janvier 2017
Journal
The New England journal of medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DE SEZE Jérôme
Tous les auteurs :
Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS,
Lien Pubmed
Résumé
An evolving understanding of the immunopathogenesis of multiple sclerosis suggests that depleting B cells could be useful for treatment. We studied ocrelizumab, a humanized monoclonal antibody that selectively depletes CD20-expressing B cells, in the primary progressive form of the disease.
Mots clés
Adolescent, Adult, Antibodies, Monoclonal, Humanized, adverse effects, Antigens, CD20, B-Lymphocytes, immunology, Brain, diagnostic imaging, Disease Progression, Double-Blind Method, Female, Humans, Infusions, Intravenous, adverse effects, Intention to Treat Analysis, Lymphocyte Count, Magnetic Resonance Imaging, Male, Middle Aged, Multiple Sclerosis, Chronic Progressive, drug therapy, T-Lymphocytes, Young Adult
Référence
N. Engl. J. Med.. 2017 01 19;376(3):209-220